

Luca Malcovati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3094461/publications.pdf>

Version: 2024-02-01

144
papers

18,899
citations

28274

55
h-index

12272

133
g-index

149
all docs

149
docs citations

149
times ranked

11808
citing authors

#	ARTICLE	IF	CITATIONS
1	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	7.2	29
2	Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of <i>SF3B1</i> -mutant HSPCs. <i>Blood Advances</i> , 2022, 6, 2992-3005.	5.2	7
3	Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms. <i>Blood</i> , 2022, 139, 2716-2720.	1.4	3
4	Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome. <i>Nature Cell Biology</i> , 2022, 24, 299-306.	10.3	47
5	Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals. <i>Blood Advances</i> , 2022, 6, 4174-4184.	5.2	8
6	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	1.4	814
7	Atomic-Level Mechanism of Pre-mRNA Splicing in Health and Disease. <i>Accounts of Chemical Research</i> , 2021, 54, 144-154.	15.6	23
8	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. <i>Leukemia</i> , 2021, 35, 2371-2381.	7.2	17
9	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	10.0	26
10	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 1452-1462.	5.2	8
11	The journey of a thousand miles begins with 1 step. <i>Blood</i> , 2021, 138, 824-826.	1.4	1
12	Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. <i>Blood</i> , 2021, 138, 1249-1257.	1.4	15
13	<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. <i>Blood Cancer Discovery</i> , 2021, 2, 500-517.	5.0	17
14	Relationship between clone metrics and clinical outcome in clonal cytopenia. <i>Blood</i> , 2021, 138, 965-976.	1.4	58
15	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. <i>Haematologica</i> , 2021, 106, 3004-3007.	3.5	29
16	Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. <i>Blood Advances</i> , 2021, 5, 3266-3278.	5.2	6
17	The EHA Research Roadmap: Malignant Myeloid Diseases. <i>HemaSphere</i> , 2021, 5, e635.	2.7	2
18	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021, 5, 3066-3075.	5.2	12

#	ARTICLE	IF	CITATIONS
19	Clonal hematopoiesis and myeloid malignancies. <i>Current Opinion in Hematology</i> , 2021, Publish Ahead of Print, 347-355.	2.5	4
20	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. <i>Blood Advances</i> , 2021, 5, 4361-4369.	5.2	9
21	Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11222.	4.1	9
22	Whole Transcriptome Analysis Identifies Distinct Gene Expression Profiles between SF3B1mut and SF3B1 wt Myelodysplastic Syndrome with Ring Sideroblasts. <i>Blood</i> , 2021, 138, 3695-3695.	1.4	0
23	Modeling Clonal Progression in SF3B1-Mutant Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 149-149.	1.4	1
24	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020, 105, 632-639.	3.5	35
25	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. <i>Haematologica</i> , 2020, 105, 640-651.	3.5	32
26	Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2020, 95, 133-143.	4.1	13
27	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	7.2	34
28	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	30.7	372
29	Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 4029-4044.	5.2	12
30	Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12332-12340.	7.1	28
31	<i>SF3B1</i>-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	1.4	195
32	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
33	Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. <i>Nature Cell Biology</i> , 2020, 22, 526-533.	10.3	30
34	EHA evaluation of the ESMOâ€”Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	4.5	10
35	Combined Cohesinâ€”RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes. <i>Cancer Discovery</i> , 2020, 10, 836-853.	9.4	51
36	Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. <i>Blood</i> , 2020, 135, 1161-1170.	1.4	30

#	ARTICLE	IF	CITATIONS
37	A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. <i>Blood</i> , 2020, 136, 33-35.	1.4	2
38	Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
39	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , 2020, 105, 2516-2523.	3.5	12
40	Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints. <i>Blood</i> , 2020, 136, 29-29.	1.4	2
41	Disclosing the Impact of Carcinogenic SF3b Mutations on Pre-mRNA Recognition Via All-Atom Simulations. <i>Biomolecules</i> , 2019, 9, 633.	4.0	23
42	CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 400-410.	3.8	58
43	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	3.5	93
44	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 2495-2505.	7.2	61
45	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. <i>Blood Advances</i> , 2019, 3, 2962-2979.	5.2	110
46	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	3.8	42
47	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. <i>Leukemia Research</i> , 2018, 67, 21-26.	0.8	4
48	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. <i>Leukemia</i> , 2018, 32, 1380-1392.	7.2	66
49	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. <i>HemaSphere</i> , 2018, 2, e150.	2.7	91
50	Infection perturbs Bach2- and Bach1-dependent erythroid lineage <i>choice</i> TM to cause anemia. <i>Nature Immunology</i> , 2018, 19, 1059-1070.	14.5	27
51	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. <i>Nature Communications</i> , 2018, 9, 3649.	12.8	140
52	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2018, 2, 2079-2089.	5.2	18
53	appreci8: a pipeline for precise variant calling integrating 8 tools. <i>Bioinformatics</i> , 2018, 34, 4205-4212.	4.1	26
54	Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. <i>Blood</i> , 2018, 132, 1225-1240.	1.4	168

#	ARTICLE	IF	CITATIONS
55	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. <i>Blood</i> , 2018, 132, 4357-4357.	1.4	1
56	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	1.4	278
57	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017, 129, 3371-3378.	1.4	379
58	Recognition of familial myeloid neoplasia in adults. <i>Seminars in Hematology</i> , 2017, 54, 60-68.	3.4	37
59	Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. <i>Leukemia and Lymphoma</i> , 2017, 58, 1711-1720.	1.3	3
60	Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. <i>Annals of Hematology</i> , 2017, 96, 1105-1112.	1.8	11
61	Gene expression and risk of leukemic transformation in myelodysplasia. <i>Blood</i> , 2017, 130, 2642-2653.	1.4	64
62	Introduction. <i>Seminars in Hematology</i> , 2017, 54, 129-132.	3.4	0
63	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	1.8	153
64	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. <i>Journal of Clinical Investigation</i> , 2017, 127, 2206-2221.	8.2	69
65	GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome. <i>Experimental Hematology</i> , 2016, 44, 590-595.e1.	0.4	11
66	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016, 128, 902-910.	1.4	140
67	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2016, 128, 1408-1417.	1.4	249
68	Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. <i>British Journal of Haematology</i> , 2016, 174, 847-858.	2.5	25
69	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. <i>Blood</i> , 2016, 128, 2096-2097.	1.4	46
70	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European LeukemiaNet MDS (EUMDS) Registry. <i>Blood</i> , 2016, 128, 3186-3186.	1.4	14
71	The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 299-307.	2.5	72
72	Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 19-25.	2.5	32

#	ARTICLE	IF	CITATIONS
73	Iron overloadâ€related heart failure in a patient with transfusionâ€dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 952-954.	0.5	4
74	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	1.4	115
75	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015, 125, 1857-1865.	1.4	153
76	The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications. <i>Current Opinion in Oncology</i> , 2015, 27, 551-559.	2.4	8
77	Validation of the revised international prognostic scoring system (<scp>IPSS</scp>â€) in patients with lowerâ€risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet <scp>MDS</scp> (<scp>EUMDS</scp>) registry. <i>British Journal of Haematology</i> , 2015, 170, 372-383.	2.5	72
78	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. <i>Nature Communications</i> , 2015, 6, 5901.	12.8	196
79	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. <i>Blood</i> , 2015, 126, 233-241.	1.4	361
80	Different Mutant Splicing Factors Cause Distinct Missplicing Events and Give Rise to Different Clinical Phenotypes in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 139-139.	1.4	2
81	SF3B1 Mutation Is an Independent Predictor of Parenchymal Iron Overload in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1678-1678.	1.4	4
82	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , 2015, 126, 907-907.	1.4	85
83	Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo. <i>Cancer Cell</i> , 2014, 25, 794-808.	16.8	272
84	Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2014, 99, 1650-1652.	3.5	14
85	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	1.4	162
86	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. <i>Blood</i> , 2014, 124, 1513-1521.	1.4	222
87	Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes. <i>Blood</i> , 2014, 124, 826-826.	1.4	6
88	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	4.1	61
89	Identification of Gene Expressionâ€Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2013, 31, 3557-3564.	1.6	45
90	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2013, 369, 2379-2390.	27.0	1,698

#	ARTICLE	IF	CITATIONS
91	Clinical and biological implications of driver mutations in myelodysplastic syndromes. <i>Blood</i> , 2013, 122, 3616-3627.	1.4	1,562
92	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013, 122, 2943-2964.	1.4	567
93	Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. <i>Blood</i> , 2013, 121, 260-269.	1.4	124
94	Refractory anemia with ring sideroblasts. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 377-385.	1.7	37
95	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	1.6	265
96	The genetic basis of myelodysplasia and its clinical relevance. <i>Blood</i> , 2013, 122, 4021-4034.	1.4	294
97	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 3005-3015.	1.4	251
98	Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. <i>Haematologica</i> , 2013, 98, 420-423.	3.5	51
99	Genetic Determinants Of Disease Phenotype In Myelodysplastic Syndromes. <i>Blood</i> , 2013, 122, 2755-2755.	1.4	0
100	Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. <i>Haematologica</i> , 2012, 97, 1036-1041.	3.5	79
101	Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool. <i>Haematologica</i> , 2012, 97, 631-632.	3.5	6
102	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 2454-2465.	1.4	2,458
103	Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2012, 120, 3830-3830.	1.4	6
104	Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 3857-3857.	1.4	0
105	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2011, 118, 6239-6246.	1.4	457
106	Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. <i>Haematologica</i> , 2011, 96, 441-449.	3.5	220
107	Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). <i>Haematologica</i> , 2011, 96, 1433-1440.	3.5	247
108	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. <i>Haematologica</i> , 2011, 96, 167-170.	3.5	60

#	ARTICLE	IF	CITATIONS
109	Classification and Prognostic Evaluation of Myelodysplastic Syndromes. <i>Seminars in Oncology</i> , 2011, 38, 627-634.	2.2	71
110	The relevance of transfusionâ€dependency in the prognostic assessment of patients with myeloid neoplasms. <i>American Journal of Hematology</i> , 2011, 86, 241-243.	4.1	6
111	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. <i>Blood</i> , 2011, 118, 2775-2775.	1.4	20
112	Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3559-3559.	1.4	15
113	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	3.5	144
114	Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 459-468.	2.2	39
115	Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts. <i>Blood</i> , 2010, 116, 1862-1862.	1.4	2
116	Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells. <i>Blood</i> , 2010, 116, 298-298.	1.4	1
117	Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2009, 27, 754-762.	1.6	225
118	Red Blood Cell Transfusion Therapy and Iron Chelation in Patients With Myelodysplastic Syndromes. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S305-S311.	1.4	19
119	Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. <i>Haematologica</i> , 2009, 94, 602-606.	3.5	41
120	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. <i>Blood</i> , 2009, 114, 3538-3545.	1.4	135
121	The Effects of Mitochondrial Ferritin Expression in Normal and Sideroblastic Erythropoiesis.. <i>Blood</i> , 2009, 114, 736-736.	1.4	0
122	Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2008, 26, 3607-3613.	1.6	270
123	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	1.4	192
124	Myelodysplastic Syndromes: Diagnosis and Staging. <i>Cancer Control</i> , 2008, 15, 4-13.	1.8	48
125	The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts. <i>PLoS ONE</i> , 2008, 3, e1970.	2.5	113
126	Reduced Intensity Conditioning with Thiotepa and Fludarabine for Allogeneic Transplantation: Evidence for Low Toxicity and Long-Lasting Disease Control in MDS with Low/Intermediate-1 IPSS Score and in AML from MDS in Complete Remission.. <i>Blood</i> , 2008, 112, 3285-3285.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2007, 25, 3503-3510.	1.6	969
128	Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, S2-S6.	0.8	117
129	Gene expression profiling of CD34 ⁺ cells in patients with the 5q ⁻ syndrome. <i>British Journal of Haematology</i> , 2007, 139, 578-589.	2.5	146
130	A Prognostic Model for Predicting the Impact of Comorbidities on Survival of Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 2453-2453.	1.4	4
131	Gene expression profiles of CD34 ⁺ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. <i>Blood</i> , 2006, 108, 337-345.	1.4	198
132	Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.. <i>Blood</i> , 2006, 108, 521-521.	1.4	12
133	Granulocyte JAK2 (V617F) Mutation Status in Myeloid Neoplasms with Ringed Sideroblasts.. <i>Blood</i> , 2006, 108, 854-854.	1.4	1
134	Novel homeobox gene recombination in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2006, 91, 290A.	3.5	0
135	Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. <i>Haematologica</i> , 2006, 91, 1588-90.	3.5	130
136	Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. <i>Journal of Clinical Oncology</i> , 2005, 23, 7594-7603.	1.6	804
137	Myelodysplastic Syndromes – Coping with Ineffective Hematopoiesis. <i>New England Journal of Medicine</i> , 2005, 352, 536-538.	27.0	306
138	Mitochondrial Ferritin Expression and Clonality of Hematopoiesis in Patients with Refractory Anemia with Ringed Sideroblasts.. <i>Blood</i> , 2005, 106, 3444-3444.	1.4	7
139	A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.. <i>Blood</i> , 2005, 106, 788-788.	1.4	18
140	The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome.. <i>Blood</i> , 2005, 106, 791-791.	1.4	2
141	Splenectomy for treatment of immune thrombocytopenic purpura. <i>Haematologica</i> , 2005, 90, 4.	3.5	75
142	Flow Cytometry Evaluation of Erythroid Dysplasia in Patients with Myelodysplastic Syndrome.. <i>Blood</i> , 2004, 104, 2365-2365.	1.4	0
143	Effects of breathing control on cardiocirculatory modulation in Caucasian lowlanders and Himalayan Sherpas. <i>European Journal of Applied Physiology</i> , 2000, 83, 481-486.	2.5	6
144	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. <i>EJHaem</i> , 0, , .	1.0	0